Enterome today announces that Pierre Bélichard, CEO, will present an overview of the Company and participate in 1-on-1 meetings with institutional investors at the following investor meetings.
PARIS, Oct. 25, 2023 (GLOBE NEWSWIRE) --
Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry platform, today announces that Pierre Bélichard, CEO, will present an overview of the Company and participate in 1-on-1 meetings with institutional investors at the following investor meetings:
- 10th China Healthcare Summit in Shanghai, China, November 2-3
– Enterome’s presentation is scheduled on November 2 at 2:45 pm in Function Room III.
- Inv€$tival Showcase in London, UK, November 13
– Enterome’s presentation is scheduled at 10:30 am on Stage 3.
- Jefferies’ London Healthcare Conference, UK, November 14-16
- 42nd J.P. Morgan Annual Healthcare Conference in San Francisco, USA, January 8-11
Additionally, Enterome’s Senior Business Development Manager, Rachel Morra, will engage in 1-on-1 meetings with potential business partners at BIO-Europe, which will take place in Munich, Germany, on November 6-8.
Contacts
| ENTEROME | MEDIA RELATIONS |
| Guillaume Bayre Head of External Communications Tel: +33 (0)1 76 21 58 15 communication@enterome.com | LifeSci Advisors LLC Sandya von der Weid (Europe) |
About Enterome
Enterome is a clinical-stage biopharmaceutical company developing breakthrough immunomodulatory drugs for the treatment of cancer and immune diseases. Enterome’s pioneering approach to drug discovery is based on its unique and powerful bacterial Mimicry drug discovery platform, which allows it to analyze and uncover new biological insights from the millions of gut bacterial proteins in constant cross-talk with the human body.
Enterome’s first-in-class small protein and peptide drug candidates modulate the immune system by closely mimicking the structure, effect or actions of specific antigens, hormones, or cytokines.
The company’s two pipelines of drug candidates include:
- OncoMimics™ peptides, a pipeline of peptide-based immunotherapies. EO2401 is in Phase 2 clinical trials in patients with glioblastoma and adrenal tumors and has demonstrated clinical proof of concept. EO2463 is in a Phase 2 clinical trial for indolent non-Hodgkin lymphomas, and has demonstrated a good safety profile with first signs of efficacy. EO4010 is in clinical development for third-line colorectal cancer and EO2040 is in a Phase 2 trial in patients suffering from colorectal cancer with ctDNA-defined, minimal residual disease.
- EndoMimics™ peptides, a pipeline of next generation bioactives acting like human hormones or cytokines, are being developed in collaboration with Nestlé Health Science, for food allergies and inflammatory bowel disease (IBD). Lead candidate, EB1010, expected to enter the clinic in 2024, is designed to improve therapeutic outcomes for patients with IBD.
Enterome employs 70 people and is headquartered in Paris, France. Since its inception, the company has raised a total of €118 million from Europe- and US-based life science investors and more than €100 million from pharmaceutical partnerships.
For more information, please visit the company’s website at: www.enterome.com
